Robin Mansukhani

Chief Executive Officer at Deciduous Therapeutics, Inc.

Commercial Services

Health Technology

Profile

Robin Mansukhani is the founder of Alzeca Biosciences, Inc. He is currently the Chief Executive Officer & Director at Deciduous Therapeutics, Inc.

Robin Mansukhani active positions

Companies	Position	Start
Deciduous Therapeutics, Inc. Deciduous Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA.	Chief Executive Officer	-

All active positions of Robin Mansukhani

Former positions of Robin Mansukhani

Companies	Position	End
Alzeca Biosciences, Inc. Alzeca Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici.	Founder	2011-12-31

See the detail of Robin Mansukhani's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Robin Mansukhani's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Alzeca Biosciences, Inc. Alzeca Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici.	Commercial Services
Deciduous Therapeutics, Inc. Deciduous Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA.	Health Technology